눈염증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Ocular Inflammation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1442863
리서치사:Transparency Market Research
발행일:2024년 01월
페이지 정보:영문 170 Pages
라이선스 & 가격 (부가세 별도)
한글목차
눈염증 치료 시장 - 리포트 대상 범위
세계의 눈염증 치료 시장에 관한 TMR의 리포트에서는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 조사하고 있습니다. 이 리포트는 세계의 눈염증 치료 시장의 2017-2031년 기간의 매출을 제공하고, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 또한 2023-2031년 세계 눈염증 치료 시장의 연평균 성장률(CAGR %)도 제공하고 있습니다.
이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분을 시행하고 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 진행했습니다. 2차 조사에는 눈염증 치료 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.
이 리포트는 세계의 눈염증 치료 시장의 경쟁 구도를 자세하게 조사하고 있습니다. 세계의 눈염증 치료 시장에서 활동하는 주요 기업이 식별되고 각각의 기업이 다양한 속성의 관점에서 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 눈염증 치료 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계 시장의 분석과 예측(2017-2031년)
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 합병과 인수
COVID-19 팬데믹이 업계에 미치는 영향
제6장 세계 시장의 분석과 예측 : 치료 유형별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 치료 유형별(2017-2031년)
코르티코스테로이드
항생제
모노클로널 항체
면역억제제
안근 마비제
항바이러스제
항진균제
진통제
시장의 매력 : 치료 유형별
제7장 세계 시장의 분석과 예측 : 질환 유형별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 질환 유형별(2017-2031년)
전포도막염
후부 포도막염
범포도막염
중간형 포도막염
상강막염/강막염
시장의 매력 : 질환 유형별
제8장 세계 시장의 분석과 예측 : 투여 방법별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 투여 방법별(2017-2031년)
국소
주사
경구
기타
시장의 매력 : 투여 방법별
제9장 세계 시장의 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 유통 채널별(2017-2031년)
원내 약국
소매 약국
온라인 약국
드러그스토어
시장의 매력 : 유통 채널별
제10장 세계 시장의 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별(2017-2031년)
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 기업 : 경쟁 매트릭스(기업 계층·규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
Bausch Health Companies, Inc.
Pfizer Inc.
Novartis AG
AbbVie, Inc.
Cipla Inc.
AKRON, Inc.
EyeGate
Alimera Sciences
EyePoint Pharmaceuticals, Inc.
KSA
영문 목차
영문목차
Ocular Inflammation Treatment Market - Scope of Report
TMR's report on the global ocular inflammation treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global ocular inflammation treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ocular inflammation treatment market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ocular inflammation treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ocular inflammation treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global ocular inflammation treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ocular inflammation treatment market.
The report delves into the competitive landscape of the global ocular inflammation treatment market. Key players operating in the global ocular inflammation treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global ocular inflammation treatment market profiled in this report.
Key Questions Answered in Global ocular inflammation treatment Market Report:
What is the sales/revenue generated by ocular inflammation treatment across all regions during the forecast period?
What are the opportunities in the global ocular inflammation treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Ocular Inflammation Treatment Market - Research Objectives and Research Approach
The comprehensive report on the global ocular inflammation treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global ocular inflammation treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ocular inflammation treatment market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ocular Inflammation Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ocular Inflammation Treatment Market Analysis and Forecast, 2017 - 2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017 - 2031
6.3.1. Corticosteroids
6.3.2. Antibiotics
6.3.3. Monoclonal Antibodies
6.3.4. Immunosppressant
6.3.5. Cycloplegic Agents
6.3.6. Antivirals
6.3.7. Antifungal
6.3.8. Analgesics
6.4. Market Attractiveness, by Treatment Type
7. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Disease Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Type, 2017 - 2031
7.3.1. Anterior Uveitis
7.3.2. Posterior Uveitis
7.3.3. Pan Uveitis
7.3.4. Intermediate Uveitis
7.3.5. Episcleritis/Scleritis
7.3.6. 7.4 Market Attractiveness, by Disease Type
8. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Mode of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Mode of Administration, 2017 - 2031
8.3.1. Topical
8.3.2. Injectable
8.3.3. Oral
8.3.4. Others
8.4. Market Attractiveness, by Mode of Administration
9. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Drug Stores
9.4. Market Attractiveness, by Distribution Channel
10. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017 - 2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Ocular Inflammation Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017 - 2031
11.2.1. Corticosteroids
11.2.2. Antibiotics
11.2.3. Monoclonal Antibodies
11.2.4. Immunosppressant
11.2.5. Cycloplegic Agents
11.2.6. Antivirals
11.2.7. Antifungal
11.2.8. Analgesics
11.3. Market Attractiveness, by Treatment Type
11.4. Market Value Forecast, by Disease Type, 2017 - 2031
11.4.1. Anterior Uveitis
11.4.2. Posterior Uveitis
11.4.3. Pan Uveitis
11.4.4. Intermediate Uveitis
11.4.5. Episcleritis/Scleritis
11.5. Market Attractiveness, by Disease Type
11.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
11.6.1. Topical
11.6.2. Injectable
11.6.3. Oral
11.6.4. Others
11.7. Market Attractiveness, by Mode of Administration
11.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.8.4. Drug Stores
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment Type
11.11.2. By Disease Type
11.11.3. By Mode of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Ocular Inflammation Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017 - 2031
12.2.1. Corticosteroids
12.2.2. Antibiotics
12.2.3. Monoclonal Antibodies
12.2.4. Immunosppressant
12.2.5. Cycloplegic Agents
12.2.6. Antivirals
12.2.7. Antifungal
12.2.8. Analgesics
12.3. Market Attractiveness, by Treatment Type
12.4. Market Value Forecast, by Disease Type, 2017 - 2031
12.4.1. Anterior Uveitis
12.4.2. Posterior Uveitis
12.4.3. Pan Uveitis
12.4.4. Intermediate Uveitis
12.4.5. Episcleritis/Scleritis
12.5. Market Attractiveness, by Disease Type
12.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
12.6.1. Topical
12.6.2. Injectable
12.6.3. Oral
12.6.4. Others
12.7. Market Attractiveness, by Mode of Administration
12.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.8.4. Drug Stores
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment Type
12.11.2. By Disease Type
12.11.3. By Mode of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Ocular Inflammation Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017 - 2031
13.2.1. Corticosteroids
13.2.2. Antibiotics
13.2.3. Monoclonal Antibodies
13.2.4. Immunosppressant
13.2.5. Cycloplegic Agents
13.2.6. Antivirals
13.2.7. Antifungal
13.2.8. Analgesics
13.3. Market Attractiveness, by Treatment Type
13.4. Market Value Forecast, by Disease Type, 2017 - 2031
13.4.1. Anterior Uveitis
13.4.2. Posterior Uveitis
13.4.3. Pan Uveitis
13.4.4. Intermediate Uveitis
13.4.5. Episcleritis/Scleritis
13.5. Market Attractiveness, by Disease Type
13.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
13.6.1. Topical
13.6.2. Injectable
13.6.3. Oral
13.6.4. Others
13.7. Market Attractiveness, by Mode of Administration
13.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.8.4. Drug Stores
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment Type
13.11.2. By Disease Type
13.11.3. By Mode of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Ocular Inflammation Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017 - 2031
14.2.1. Corticosteroids
14.2.2. Antibiotics
14.2.3. Monoclonal Antibodies
14.2.4. Immunosppressant
14.2.5. Cycloplegic Agents
14.2.6. Antivirals
14.2.7. Antifungal
14.2.8. Analgesics
14.3. Market Attractiveness, by Treatment Type
14.4. Market Value Forecast, by Disease Type, 2017 - 2031
14.4.1. Anterior Uveitis
14.4.2. Posterior Uveitis
14.4.3. Pan Uveitis
14.4.4. Intermediate Uveitis
14.4.5. Episcleritis/Scleritis
14.5. Market Attractiveness, by Disease Type
14.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
14.6.1. Topical
14.6.2. Injectable
14.6.3. Oral
14.6.4. Others
14.7. Market Attractiveness, by Mode of Administration
14.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.8.4. Drug Stores
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment Type
14.11.2. By Disease Type
14.11.3. By Mode of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Ocular Inflammation Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2017 - 2031
15.2.1. Corticosteroids
15.2.2. Antibiotics
15.2.3. Monoclonal Antibodies
15.2.4. Immunosppressant
15.2.5. Cycloplegic Agents
15.2.6. Antivirals
15.2.7. Antifungal
15.2.8. Analgesics
15.3. Market Attractiveness, by Treatment Type
15.4. Market Value Forecast, by Disease Type, 2017 - 2031
15.4.1. Anterior Uveitis
15.4.2. Posterior Uveitis
15.4.3. Pan Uveitis
15.4.4. Intermediate Uveitis
15.4.5. Episcleritis/Scleritis
15.5. Market Attractiveness, by Disease Type
15.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
15.6.1. Topical
15.6.2. Injectable
15.6.3. Oral
15.6.4. Others
15.7. Market Attractiveness, by Mode of Administration
15.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.8.4. Drug Stores
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment Type
15.11.2. By Disease Type
15.11.3. By Mode of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Bausch Health Companies, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Novartis AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AbbVie, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Cipla Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. AKRON, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. EyeGate
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Alimera Sciences
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. EyePoint Pharmaceuticals, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
